178 related articles for article (PubMed ID: 36412424)
1. Evaluation of clinically significant prostate cancer using biparametric magnetic resonance imaging: An evolving concept.
Mahajan M; Gupta V; Gupta P; Sharma P; Abrol D
J Cancer Res Ther; 2022; 18(6):1640-1645. PubMed ID: 36412424
[TBL] [Abstract][Full Text] [Related]
2. Can high b-value 3.0 T biparametric MRI with the Simplified Prostate Image Reporting and Data System (S-PI-RADS) be used in biopsy-naïve men?
Wang G; Yu G; Chen J; Yang G; Xu H; Chen Z; Wang G; Bai Z
Clin Imaging; 2022 Aug; 88():80-86. PubMed ID: 34243992
[TBL] [Abstract][Full Text] [Related]
3. The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.
Wang ZB; Wei CG; Zhang YY; Pan P; Dai GC; Tu J; Shen JK
Biomed Res Int; 2021; 2021():3995789. PubMed ID: 34671673
[TBL] [Abstract][Full Text] [Related]
4. Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy.
Thaiss WM; Moser S; Hepp T; Kruck S; Rausch S; Scharpf M; Nikolaou K; Stenzl A; Bedke J; Kaufmann S
World J Urol; 2022 Oct; 40(10):2431-2438. PubMed ID: 35922717
[TBL] [Abstract][Full Text] [Related]
5. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
6. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
7. Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: Prostate Imaging Reporting and Data System Version 1 versus Version 2.
Feng ZY; Wang L; Min XD; Wang SG; Wang GP; Cai J
Chin Med J (Engl); 2016 Oct; 129(20):2451-2459. PubMed ID: 27748338
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
Lim CS; Abreu-Gomez J; Carrion I; Schieda N
AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
[No Abstract] [Full Text] [Related]
9. Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1.
Tamada T; Kido A; Yamamoto A; Takeuchi M; Miyaji Y; Moriya T; Sone T
J Magn Reson Imaging; 2021 Jan; 53(1):283-291. PubMed ID: 32614123
[TBL] [Abstract][Full Text] [Related]
10. Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.
Schaudinn A; Gawlitza J; Mucha S; Linder N; Franz T; Horn LC; Kahn T; Busse H
Eur J Radiol; 2019 Jul; 116():180-185. PubMed ID: 31153562
[TBL] [Abstract][Full Text] [Related]
11. Biparametric 3T Magnetic Resonance Imaging for prostatic cancer detection in a biopsy-naïve patient population: a further improvement of PI-RADS v2?
Stanzione A; Imbriaco M; Cocozza S; Fusco F; Rusconi G; Nappi C; Mirone V; Mangiapia F; Brunetti A; Ragozzino A; Longo N
Eur J Radiol; 2016 Dec; 85(12):2269-2274. PubMed ID: 27842676
[TBL] [Abstract][Full Text] [Related]
12. Comparison of multiparametric and biparametric MRI of the prostate: are gadolinium-based contrast agents needed for routine examinations?
Junker D; Steinkohl F; Fritz V; Bektic J; Tokas T; Aigner F; Herrmann TRW; Rieger M; Nagele U
World J Urol; 2019 Apr; 37(4):691-699. PubMed ID: 30078170
[TBL] [Abstract][Full Text] [Related]
13. Prospective nonrandomized study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy to magnetic resonance imaging with subsequent MRI-guided biopsy in biopsy-naïve patients.
Castellucci R; Linares Quevedo AI; Sánchez Gómez FJ; Díez Rodríguez J; Cogorno L; Cogollos Acuña I; Salmerón Béliz I; Muñoz Fernández de Legaría M; Martínez Piñeiro L
Minerva Urol Nefrol; 2017 Dec; 69(6):589-595. PubMed ID: 29094851
[TBL] [Abstract][Full Text] [Related]
14. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.
Faiella E; Santucci D; Greco F; Frauenfelder G; Giacobbe V; Muto G; Zobel BB; Grasso RF
Radiol Med; 2018 Feb; 123(2):143-152. PubMed ID: 29019021
[TBL] [Abstract][Full Text] [Related]
15. Impact of qualitative, semi-quantitative, and quantitative analyses of dynamic contrast-enhanced magnet resonance imaging on prostate cancer detection.
Ziayee F; Ullrich T; Blondin D; Irmer H; Arsov C; Antoch G; Quentin M; Schimmöller L
PLoS One; 2021; 16(4):e0249532. PubMed ID: 33819295
[TBL] [Abstract][Full Text] [Related]
16. Value of Dynamic Contrast-Enhanced (DCE) MR Imaging in Peripheral Lesions in PI-RADS-4 Patients.
Ullrich T; Quentin M; Arsov C; Laqua N; Abrar D; Hiester A; Albers P; Antoch G; Schimmöller L
Rofo; 2020 May; 192(5):441-447. PubMed ID: 31622990
[TBL] [Abstract][Full Text] [Related]
17. Comparison of biparametric MRI to full multiparametric MRI for detection of clinically significant prostate cancer.
Sherrer RL; Glaser ZA; Gordetsky JB; Nix JW; Porter KK; Rais-Bahrami S
Prostate Cancer Prostatic Dis; 2019 May; 22(2):331-336. PubMed ID: 30413806
[TBL] [Abstract][Full Text] [Related]
18. High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility.
van der Leest M; Israël B; Cornel EB; Zámecnik P; Schoots IG; van der Lelij H; Padhani AR; Rovers M; van Oort I; Sedelaar M; Hulsbergen-van de Kaa C; Hannink G; Veltman J; Barentsz J
Eur Urol; 2019 Nov; 76(5):574-581. PubMed ID: 31167748
[TBL] [Abstract][Full Text] [Related]
19. Low cancer yield in PI-RADS 3 upgraded to 4 by dynamic contrast-enhanced MRI: is it time to reconsider scoring categorization?
Messina E; Pecoraro M; Laschena L; Bicchetti M; Proietti F; Ciardi A; Leonardo C; Sciarra A; Girometti R; Catalano C; Panebianco V
Eur Radiol; 2023 Aug; 33(8):5828-5839. PubMed ID: 37045981
[TBL] [Abstract][Full Text] [Related]
20. PI-RADS v2 and periprostatic fat measured on multiparametric magnetic resonance imaging can predict upgrading in radical prostatectomy pathology amongst patients with biopsy Gleason score 3 + 3 prostate cancer.
Zhai L; Fan Y; Sun S; Wang H; Meng Y; Hu S; Wang X; Yu W; Jin J
Scand J Urol; 2018; 52(5-6):333-339. PubMed ID: 30895901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]